Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2.
NCT ID: NCT04186273
Last Updated: 2019-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
50 participants
INTERVENTIONAL
2019-12-05
2021-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Total of 6, categorized by type of wound and treatment allocation.
Description of Study Arms:
The quality of tissue repair and scarring will be evaluated in two different, bisected post-surgical sites on the same Participant. Each wound site represents a Study Arm. Each wound site will receive two treatments, one of which is always a vehicle. In total the two wound types provide a total of 6 Study Arms for statistical analysis.
Arm 1 / Wound Type 1 (skin grafted wounds: 3-treatment groups): The wound site (injury) that requires skin grafting surgery to remove normal, uninjured skin from the same Participant to cover and repair a deep wound (a "skin graft").
Arm 2 / Wound Type (donor skin graft harvest site; 3-treatment groups): A surgical wound where a piece of normal skin is removed at uniform depth using a dermatome to harvest a skin graft ("skin graft harvest site").
The bisected wound site is randomly assigned either a control or FS2 cream treatment.
Treatment Groups: Each wound site will be used to investigate and compare three different treatments. Participants will apply the investigated treatments ("IP") as directed to allocated bisected sections of the skin grafted wound and donor wound site for 90 days. Follow-on assessments will be conducted with additional study visits on Days 180 and 270 (study endpoint).
There are four (4) differently labelled products as follows:
Treatment-1 (IP1) A single, daily application of a moisturizing cream-base.
Treatment-2 (IP2) A single, daily application of a moisturizing cream-base with FS2 (0.50% w/w).
Treatment-3 (IP3) A single, daily application of a moisturizing cream-base with FS2 (0.25% w/w). IP3 will have two different product labels to conceal the identity of the vehicle.
Control-cream (IP1), and treatments IP2 and IP3 each containing 0.50%w/w or 0.25%w/w FS2 respectively, will be topically applied to designated treatment sites once per day for a period of 90 days. Investigator and participant will be blinded from both identity of treatment product and randomized location. Each participant will be provided a different cream for each bisected-site for a total of four (4) differently labelled creams; two for the donor site, and two for the skin grafted site. Participants will discuss and be informed/reminded at each visit about study design, responsibilities, possible adverse events, proper daily wound care and cream application methods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Donor Site Wound, Vehicle
A vehicle moisturizing cream base applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
Vehicle moisture balancing base
Vehicle base without FS2.
Donor Site Wound, FS2 0.25
A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
Fibrosis-Inhibiting-Compound-FS2
There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
Donor Site Wound, FS2 0.5
A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested)
Fibrosis-Inhibiting-Compound-FS2
There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
Skin Graft Wound, Vehicle
A vehicle moisturizing cream base applied to a bisected area of the skin grafted wound site.
Vehicle moisture balancing base
Vehicle base without FS2.
Skin Graft Wound, FS2 0.25
A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the skin grafted wound site.
Fibrosis-Inhibiting-Compound-FS2
There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
Skin Graft Wound, FS2 0.5
A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the skin grafted wound site.
Fibrosis-Inhibiting-Compound-FS2
There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fibrosis-Inhibiting-Compound-FS2
There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
Vehicle moisture balancing base
Vehicle base without FS2.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Adult, male and female trauma patients
3. Ages 18 to 65 years of age
4. Fluent in English (able to consent without a translator)
5. Isolated skin wound of 3% Total Body Surface Area
6. Participant requires partial thickness skin graft (meshed/non-meshed), face and genitalia excluded.
7. Grafted skin is between 100 cm2 and 600 cm2
8. Maximum skin graft expansion ratio is 1:1.5
Exclusion Criteria
2. Require an English translator to lawfully consent to the study and its requirements
3. Treatment sights (skin graft sights) located on the face and genitalia
4. Expected to be medically unstable for the duration of the study period and an additional 1-month thereafter
5. Pregnant, or attempting to become pregnant
6. Known immunosuppression or immunosuppressive illness
7. Subjects who had taken part in a clinical trial within 3 months prior to admission to this trial or who are currently participating in a clinical trial, whether an investigational drug was used or not.
8. Subjects who had any clinical evidence of severe ongoing or prolonged depression or mental illness
9. Subjects who smoke more than 20 cigarettes a day
10. Subjects who demonstrated evidence of drug abuse
11. Any other diagnosis, condition, physical or geographical limitation with the participant that may render, or increases the likelihood of rendering, him/her unable to complete the entire study.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of British Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anthony Papp
Medical Director, BCPFF Burn Unit and Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anthony Papp, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of British Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VGH Burn Unit
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tesnim Sairi
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Papp A, Hartwell R, Evans M, Ghahary A. The Safety and Tolerability of Topically Delivered Kynurenic Acid in Humans. A Phase 1 Randomized Double-Blind Clinical Trial. J Pharm Sci. 2018 Jun;107(6):1572-1576. doi: 10.1016/j.xphs.2018.01.023. Epub 2018 Feb 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H16-02491
Identifier Type: -
Identifier Source: org_study_id